China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026)
China Pharma Holdings (CPHI) reported Current Deferred Revenue of $61746.0 for Q1 2026, down 46.04% on a YoY basis from $114435.0 in Q1 2025, and down 44.66% quarter-over-quarter from $111580.0 in Q4 2025.
China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Current Deferred Revenue for 17 years, with the latest figure at $61746.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 46.04% year-over-year to $61746.0; the trailing twelve-month figure through Mar 2026 stood at $61746.0 (down 46.04% YoY), and the FY2025 full-year result was $111580.0, down 31.21% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $61746.0, down from $111580.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $520295.0 in Q4 2022, with the low at $24920.0 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $130953.5 across 5 years, with a median of $112357.0 in 2024.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue tumbled 85.52% — and 2025, when it soared 385.2%.
- China Pharma Holdings' Current Deferred Revenue stood at $520295.0 in 2022, then sank by 82.6% to $90507.0 in 2023, then surged by 79.22% to $162208.0 in 2024, then slumped by 31.21% to $111580.0 in 2025, then plunged by 44.66% to $61746.0 in 2026.
- The last three Current Deferred Revenue figures came in at $61746.0 (Q1 2026), $111580.0 (Q4 2025), and $120912.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,746.00 |
| Dec 31, 2025 | 111,580.00 |
| Sep 30, 2025 | 120,912.00 |
| Jun 30, 2025 | 77,683.00 |
| Mar 31, 2025 | 114,435.00 |
| Dec 31, 2024 | 162,208.00 |
| Sep 30, 2024 | 24,920.00 |
| Jun 30, 2024 | 101,056.00 |
| Mar 31, 2024 | 112,357.00 |
| Dec 31, 2023 | 90,507.00 |
| Sep 30, 2023 | 172,110.00 |
| Jun 30, 2023 | 61,334.00 |
| Mar 31, 2023 | 136,681.00 |
| Dec 31, 2022 | 520,295.00 |
| Sep 30, 2022 | 84,048.00 |
| Jun 30, 2022 | 138,238.00 |
| Mar 31, 2022 | 136,099.00 |
| Dec 31, 2021 | 210,028.00 |
| Sep 30, 2021 | 420,039.00 |
| Jun 30, 2021 | 525,579.00 |